Aytu BioPharma Reports $13.9 Million Revenue, Enters Exclusive Agreement for EXXUA

Aytu BioPharma, Inc. reported a net revenue of $13.9 million for the three months ended September 30, 2025, a decrease of 16% from $16.6 million in the same period last year. The decline in revenue was primarily attributed to a one-time increase of $3.3 million in the previous fiscal year related to adjustments in estimated variable consideration for the ADHD product portfolio. The company's gross profit also fell to $9.2 million, down from $12 million, reflecting a gross profit margin of 66%, compared to 72% in the prior year.

Operating expenses decreased to $10.7 million from $12.9 million, driven by reductions in selling and marketing costs, general and administrative expenses, and a complete halt in research and development spending. The company reported a loss from operations of $1.5 million, compared to a loss of $930,000 in the same quarter of the previous year. However, Aytu recorded a net income of $2 million from continuing operations, a significant increase from $1.1 million in the prior year, largely due to a gain of $3.8 million from derivative warrant liabilities.

In terms of strategic developments, Aytu has entered into an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. to commercialize EXXUA, a new antidepressant expected to launch in the second quarter of fiscal 2026. This product is anticipated to be a key growth driver for the company, which is focusing on its ADHD and Pediatric product portfolios while winding down unprofitable operations. The company has also established international collaborations for its ADHD products in Israel and Canada, which are expected to enhance its market presence.

As of September 30, 2025, Aytu's total assets stood at $125 million, with current assets increasing to $81.1 million from $79.2 million at the end of the previous fiscal year. The company’s cash and cash equivalents rose to $32.6 million, up from $31 million. Total liabilities increased to $101.8 million, primarily due to a rise in accounts payable and accrued liabilities. The company’s stockholders’ equity improved to $23.2 million, reflecting a positive shift in its financial position.

Looking ahead, Aytu BioPharma aims to accelerate the growth of its commercial business and achieve positive operating cash flows. The company has suspended active development of clinical programs to focus on the commercialization of EXXUA and its existing product lines. Management remains cautious about external economic factors, including inflation and supply chain disruptions, which could impact operations in the near term. The company plans to continue evaluating strategic partnerships and potential acquisitions to enhance shareholder value.